Marinus Pharmaceuticals (MRNS) shares were up premarket Monday after the company said it signed a deal under which Immedica Pharma will acquire all issued and outstanding shares for $0.55 a share.
Under the terms of the deal, Immedica Pharma will initiate a cash tender offer for all MRNS shares, corresponding to an implied enterprise value of $151 million, the companies said.
The companies said they intend to close the transaction in Q1 and that Marinus' board of directors unanimously approved the merger plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.